

August 21, 2020

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Madam/ Sir,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

“Strides receives USFDA approval for Ursodiol Tablets”

Thanks & Regards,
For **Strides Pharma Science Limited**,



Manjula Ramamurthy
Company Secretary



Encl. As above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India
Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India
Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

info@strides.com; www.strides.com

Strides receives USFDA approval for Ursodiol Tablets

***Product to be launched immediately
To be marketed by Strides Pharma Inc. in the US market***

Bengaluru, August 21, 2020 – Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for ***Ursodiol Tablets USP, 250 mg and 500 mg*** from the United States Food & Drug Administration (USFDA). The product is a generic version of Urso 250[®] Tablets, 250 mg and Urso Forte Tablets[®], 500 mg, of Allergan Sales, LLC.

According to IQVIA MAT June 2020 data, the US market for Ursodiol Tablets USP, 250 mg and 500 mg is approximately US\$ 35 Mn. The product will be manufactured at the company's flagship facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.

The company has 126 cumulative ANDA filings with USFDA of which 88 ANDAs have been approved and 38 are pending approval.

About Ursodiol Tablets

Ursodiol tablets are indicated for the treatment of patients with Primary Biliary Cirrhosis (PBC).

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on "difficult to manufacture" products that are sold in over 100 countries. Additional information is available at the Company's website at www.strides.com

For further information, please contact:

Strides

Badree Komandur

Executive Director – Finance & Group CFO
+91 80 6784 0747

Investor Relations

Sandeep Baid: +91 80 6784 0791

Email: Sandeep.baid@strides.com

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17, Vashi,
Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta Road,
Bangalore – 560 076

Corporate Communication

Usha Iyer: +91 9987444106

Email: usha.iyer@strides.com

PR Consultancy

Fortuna PR

K Srinivas Reddy: +91 90005 27213

srinivas@fortunapr.com

K Priya: +91 95354 25418

priya@fortunapr.com